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Degree of Change in Mitral Regurgitation (MR) Following TAVI
DEGREE OF
MR
No. of Pt
Pre (%)
No. of Pt
Post (%)
P.
VAL.
No MR 3 (6%) 16 (32%) 0.001
Mild MR 20 (40%) 22 (44%) NS
Moderate MR 21 (42%) 10 (20%) 0.001
Severe MR 6 (12%) 2 (4%) NS
TF - TRANSFEMORAL
TA - TRANSAPICAL
NS - not significant
S - Significant
Conclusion: Degree of MR Improvement achieved in 56% patient. The predictor factor
that influence the reduction of severity of MR Post TAVI are a) Hypertension b) change
in the degree of Pulmonary Artery Pressure post TAVI.
However the eteology of MR, change in aortic gradient and change of LV function
post TAVI were not significant predictor.
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Factors Predicting Prolonged Hospital Stay After TAVI
Margarita Sirotina, Johannes Weber, Malte Buergstein, Ilona Hofmann, Horst Sievert
CardioVascular Center, Frankfurt am Main, Germany
Background: Transcatheter aortic valve implantation (TAVI) has become a valuable
alternative to aortic valve replacement (AVR) for surgical high-risk patients with severe
aortic stenosis. Due to technical improvements and increased operator experience the valve
implantation success has become very high. Nevertheless, the post procedural recovery in
these elderly patients is often prolonged. We aimed to evaluate clinical and demographic
predictors of a prolonged hospital stay in patients undergoing TAVI.
Methods: We included 187 consecutive patients with severe aortic stenosis who
underwent TAVI. The valve was implanted by transfemoral technic in 180 (96.3%),
transapical in 2 (1.1%) and via the subclavian artery in 5 (2.7%) patients. We implanted
160 (85.6%) CoreValve and 27 (14.4%) Edwards Sapien prostheses. Logistic regression
was used to determine the factors affecting length of stay longer than median.
Results: Median of length of stay was 7 days. Pulmonary hypertension above 60mmHg,
prior ischemic stroke, EuroSCORE II above median (5.3%) and previous cardiac surgery
did not have significant influence on the length of hospital stay (LOS). The following
parameters could be identified as predictors of a hospital stay  7 days (table 1).
Conclusion: Age above 85, STS-Score above median (5.6%), female gender, state of
chronic renal failure 3, logistic EuroSCORE above median (14.7%) are associated with
an increased risk of a longer hospital stay after TAVI. Independent predicting risk factors
are only the STS Score above median (5.6%) and the age above 85.
Table 1. Predictors of LOS > 7 days
Odds
ratio
95%
CI p-value
State of chronic renal failure  3 1.9 1.1-3.5 0.03
STS-Score1  median (5.6%) 2.5 1.4-4.5 0.003
EuroSCORE Log2  median (14.7%) 1.9 1.1-3.4 0.03
Age  85 2.6 1.3-5.5 0.01
Female Gender 2.0 1.1-3.6 0.03
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Objectives: The aim of this study was to compare surgical outcome of patients with
previous cardiac surgery undergoing transapical aortic valve implantation (Redo-TAVI) to
those undergoing classic aortic valve replacement (Redo-AVR) by using propensity
analysis.
Background: TAVI has been suggested as an alternative to surgery in elderly patients
considered inoperable or high risk for surgical aortic valve replacement.
Methods: From January 2005 through Mai 2012, 52 high risk patients underwent
Redo-TAVI using a pericardial xenograft fixed within a stainless steel, balloon-
expandable stent (Edwards SAPIENTM). During the same period of time 167 patients
underwent classic Redo-SAVR. Logistic regression analysis was used to identify covariates
among 10 baseline patient variables including the type of initial surgery. Using the
significant regression coefficients, each patient’s propensity score was calculated, allowing
selectively matched subgroups of 40 patients each. Initial surgery included CABG in 29
patients and valve surgery in 11 patients in each group. Operative outcomes were analyzed
for differences. Follow-up was 42 years and 100% complete.
Results: Postoperative chest tube drainage (163214 vs 562332 ml/24h, p: 0.024),
incidence of permanent postoperative neurologic events (0 vs 13%, p: 0.012) and 30 day
mortality (10 vs 20%, p: 0.046) was lower in patients with Redo-TAVI as compared to
Redo-AVR. There was a trend towards a decreased ventilation time and need of
transfusion of packed red blood cell concentrates in the Redo-TAVI group (p: 0.078).
One patient in the Redo-TAVI group required temporary cardiopulmonary bypass
support. During late follow up there was no significant difference regarding mortality (10
vs 13%) and incidence of stroke (0 vs 3%, p:0.11).
Conclusions: Despite the limited number of patients, current data suggest a faster
postoperative recovery and reduced perioperative morbidity and mortality with Redo-
TAVI as compared to classic Redo-AVR. This evolving approach has reduced surgical
trauma and may be particularly applicable to elderly high risk patients with previous
cardiac surgery.
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Long-Term Results Following Transcatheter Aortic Valve Replacement (TAVR)
Pablo Codner, Abid Asali, Hanna Vaknin-Assa, Yaron Shapira, Gabriel Greenberg,
Katia Orbin, Marina Kupershmidt, Tamir Bental, Alexander Battler, Alexander Sagie,
Ran Kornowski
Rabin Medical Center, Petah Tikwa, Israel
Background and Aim: TAVR is an emerging technique for the treatment of severe
symptomatic aortic stenosis (AS). Few data reported the long-term outcomes of patients
undergoing TAVR. Thus, we aimed to focus on the prolonged results of the TAVR
procedure.
Methods: We analyzed the outcomes of 190 TAVR treated patients that were followed
up to 3 years. All patients were at very high risk for surgical valve replacement. The
Medtronic-CoreValve device was utilized in 64.2% and the Edwards-SAPIEN device in
35.7% of patients. The primary end point was death from any cause during follow up.
Results: The mean (SD) patient age was 82.15.7 years (60.5% female). Procedural
success rate (per VARC) was 96.8%. At 30 days, all-cause mortality was 3.1% and stroke
rates 3.7%. Two years follow up was obtained in 112 patients. All-cause mortality was
recorded in 13.6% of treated patients (4.2% cardiac mortality). No significant differences
in mortality were found when angioplasty was performed prior or during TAVR
compared to TAVR alone. Multivariate analysis showed that increased baseline creatinine
(HR 1.47; 95% CI 0.92-2.34; p0.099) and increased LogEuroSCORE (HR 1.03; 95%
CI 1.01-1.07; p0.017) predicted all-cause mortality.
Conclusion: According to our clinical experiences, the long-term prognosis of ‘all
comers’ TAVR patients is favorable.
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